Administrative Core
行政核心
基本信息
- 批准号:8379692
- 负责人:
- 金额:$ 104.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-01 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAntineoplastic AgentsApoptosisBiological SciencesBiologyCellsChemicalsConsultationsCore FacilityDataDepositionDoctor of MedicineDoctor of PhilosophyDrug Discovery GroupsEnsureFoundationsFundingGenomicsGoalsGrantHeadHuman ResourcesInstitutesLeadLeadershipLibrariesMethodologyMissionMolecular BankPhaseProgram DevelopmentProtocols documentationPubChemResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResource SharingResourcesRoleScientistScreening procedureTimeTimeLineUnited States National Institutes of HealthWorkexperiencehigh throughput screeningoperationoutreachprogramsskills
项目摘要
UNIT 5. ADMINISTRATION
Unit 5 provides leadership for the Burnham Center, and ensures coordination with other components of
MLPCN. Dr. John Reed heads Unit 5, with Dr. Kristiina Vuori as co-Director. This leadership team was highly
successful in the MLSCN Phase, and has impressive administrative skills, including direct experience in
operating large collaborative research projects. Daily work-flow of the Center is coordinated by the Project
Manager, Dr. Thomas Chung. Dr. Shakeela Dad functions as a full-time Outreach Coordinator for the Center.
第五单元.管理
第5股为伯纳姆中心提供领导,并确保与其他组成部分的协调,
MLPCN。约翰·里德博士领导第5股,克里斯蒂娜·沃里博士担任联合主任。这支领导团队高度
在MLSCN阶段取得成功,并具有令人印象深刻的管理技能,包括直接经验
开展大型合作研究项目。中心的日常工作流程由项目协调
经理,托马斯钟医生。Shakeela Dad博士是该中心的全职外联协调员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Jackson其他文献
Michael Jackson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Jackson', 18)}}的其他基金
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
靶向端粒酶逆转录酶 (TERT) 的突变启动子
- 批准号:
10677899 - 财政年份:2023
- 资助金额:
$ 104.47万 - 项目类别:
Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse
脑渗透性 GPR88 激动剂作为阿片类药物滥用的新型疗法
- 批准号:
10517225 - 财政年份:2022
- 资助金额:
$ 104.47万 - 项目类别:
Preventing Tau uptake by novel inhibitors of tau binding to LRP1
通过与 LRP1 结合的新型 tau 抑制剂阻止 Tau 摄取
- 批准号:
10343473 - 财政年份:2022
- 资助金额:
$ 104.47万 - 项目类别:
Preventing Tau uptake by novel inhibitors of tau binding to LRP1
通过与 LRP1 结合的新型 tau 抑制剂阻止 Tau 摄取
- 批准号:
10581565 - 财政年份:2022
- 资助金额:
$ 104.47万 - 项目类别:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
基于药物伴侣的策略,用于识别脑源性孤儿 GPCR 的化学探针
- 批准号:
10183333 - 财政年份:2020
- 资助金额:
$ 104.47万 - 项目类别:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
基于药物伴侣的策略,用于识别脑源性孤儿 GPCR 的化学探针
- 批准号:
10400863 - 财政年份:2020
- 资助金额:
$ 104.47万 - 项目类别:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
基于药物伴侣的策略,用于识别脑源性孤儿 GPCR 的化学探针
- 批准号:
10595660 - 财政年份:2020
- 资助金额:
$ 104.47万 - 项目类别:
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs
基于药物伴侣的策略,用于识别脑源性孤儿 GPCR 的化学探针
- 批准号:
10037550 - 财政年份:2020
- 资助金额:
$ 104.47万 - 项目类别:
Optimization and Characterization of "MYC Degraders" for Pediatric Medulloblastoma
小儿髓母细胞瘤“MYC 降解剂”的优化和表征
- 批准号:
10612251 - 财政年份:2020
- 资助金额:
$ 104.47万 - 项目类别:
Developing Choroid Plexus-Based Tools and Drug Screens
开发基于脉络丛的工具和药物筛选
- 批准号:
9304373 - 财政年份:2016
- 资助金额:
$ 104.47万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 104.47万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 104.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 104.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 104.47万 - 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
- 批准号:
2720213 - 财政年份:1999
- 资助金额:
$ 104.47万 - 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
- 批准号:
6513197 - 财政年份:1999
- 资助金额:
$ 104.47万 - 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
- 批准号:
7101017 - 财政年份:1999
- 资助金额:
$ 104.47万 - 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
- 批准号:
6894842 - 财政年份:1999
- 资助金额:
$ 104.47万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 104.47万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 104.47万 - 项目类别: